Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

MUSC health has established the Rena N. Grant Sickle Cell Center to help treat those suffering from sickle cell disease. This ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

The Medical University of South Carolina is expanding its access to state-supported Sickle Cell programs for “warriors,” or ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

How does the public feel about breakthrough technologies like AI, cell and gene therapy, cultivated meat, and new genomic techniques? 13,000 people weighed in worldwide.

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...